BioSpace News Archive

Growth of the global fetal monitoring market is attributed to increase in incidences of stillbirths, multiple pregnancy, late maternal age, technological advancements, and increase in emphasis on continuous fetal monitoring.

Increase in implementation of smartphones and tablets along with healthcare apps, surge in incidences of chronic diseases, and growth in need to control healthcare costs propel the growth of the global digital therapeutics market.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical and commercial stage biopharmaceutical company developing new therapies to treat cancer, pain (non-opioid treatments), autoimmune disease and COVID-19, today announced promising preclinical results for its mRNA vaccine against SARS-CoV-2.

Kepro announced today that it has entered into a definitive agreement to acquire eQHealth Solutions, LLC.

Neuromod Devices Ltd, the Irish medical device company specialising in the treatment of tinnitus, has announced the establishment of Neuromod USA Inc., a subsidiary headquartered in Oak Brook, Illinois.

Herbalife Nutrition today announced that experts from its staff of over 300 scientists will present emerging research to scientific and regulatory attendees at the AOAC (Association of Official Agricultural Chemists) International Annual Meeting taking place August 27-September 2, 2021.

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, announced that management will participate in the following upcoming investor conferences:

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), and Innovent Biologics, Inc. (HKEX: 01801), today announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will participate at the Morgan Stanley 19th Annual Global Healthcare Conference on Thursday, September 9, 2021 at 3:30 p.m. Eastern Time.

MorphoSys AG and Incyte announced that the European Commission has granted conditional marketing authorization for Minjuvi® in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.